Royce & Associates’s Arcosa ACA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$133M Buy
1,252,310
+17,855
+1% +$2.03M 1.31% 1
2025
Q4
$131M Sell
1,234,455
-32,636
-3% -$3.29M 1.33% 1
2025
Q3
$119M Buy
1,267,091
+4,652
+0.4% +$433K 1.18% 1
2025
Q2
$109M Buy
1,262,439
+8,351
+0.7% +$699K 1.12% 2
2025
Q1
$96.7M Buy
1,254,088
+14,839
+1% +$1.36M 1.05% 3
2024
Q4
$120M Sell
1,239,249
-128,525
-9% -$12.9M 1.11% 1
2024
Q3
$130M Sell
1,367,774
-61,136
-4% -$5.34M 1.18% 2
2024
Q2
$119M Buy
1,428,910
+1,643
+0.1% +$137K 1.11% 2
2024
Q1
$123M Sell
1,427,267
-31,824
-2% -$2.59M 1.09% 2
2023
Q4
$121M Buy
1,459,091
+56,055
+4% +$4.11M 1.11% 1
2023
Q3
$101M Sell
1,403,036
-21,310
-1% -$1.62M 1.03% 2
2023
Q2
$108M Sell
1,424,346
-48,686
-3% -$3.27M 1.05% 2
2023
Q1
$93M Sell
1,473,032
-58,500
-4% -$3.43M 0.93% 4
2022
Q4
$83.2M Sell
1,531,532
-204,172
-12% -$12.1M 0.87% 8
2022
Q3
$99.2M Sell
1,735,704
-213,857
-11% -$11.9M 1.12% 1
2022
Q2
$90.5M Buy
1,949,561
+51,346
+3% +$2.69M 0.93% 5
2022
Q1
$109M Buy
1,898,215
+100,732
+6% +$5.19M 0.92% 4
2021
Q4
$94.7M Buy
1,797,483
+169,334
+10% +$9.05M 0.71% 10
2021
Q3
$81.7M Buy
1,628,149
+129,979
+9% +$6.74M 0.61% 16
2021
Q2
$88M Sell
1,498,170
-130,910
-8% -$8.1M 0.6% 11
2021
Q1
$106M Buy
1,629,080
+44,398
+3% +$2.73M 0.71% 6
2020
Q4
$87M Sell
1,584,682
-18,524
-1% -$945K 0.72% 9
2020
Q3
$70.7M Buy
1,603,206
+268,280
+20% +$11.8M 0.76% 11
2020
Q2
$56.3M Buy
1,334,926
+291,376
+28% +$11.2M 0.62% 21
2020
Q1
$41.5M Sell
1,043,550
-55,685
-5% -$2.35M 0.57% 35
2019
Q4
$49M Sell
1,099,235
-63,993
-6% -$2.46M 0.44% 52
2019
Q3
$39.8M Buy
1,163,228
+78,190
+7% +$2.71M 0.37% 61
2019
Q2
$40.8M Sell
1,085,038
-45,203
-4% -$1.55M 0.37% 60
2019
Q1
$34.5M Buy
1,130,241
+39,989
+4% +$1.22M 0.29% 78
2018
Q4
$30.2M Buy
+1,090,252
New +$30M 0.27% 82

Other funds holding ACA

Royce & Associates's ACA Position: Q1 2026 in Review

Royce & Associates increased its Arcosa (ACA) stake by 1.4% in Q1 2026, buying an estimated $2.03M and bringing the position to 1,252,310 shares worth $133M. The position accounts for 1.31% of the portfolio, ranked #1.

Royce & Associates first reported a position in ACA in Q4 2018 and has held it in 30 quarters since. 372 funds tracked by Wall St. Rank hold ACA as of Q1 2026.

  • Royce & Associates held 1,252,310 shares of Arcosa worth $133M as of Q1 2026.
  • Royce & Associates bought 17,855 Arcosa shares in Q1 2026, an estimated $2.03M.
  • Arcosa made up 1.31% of Royce & Associates's portfolio in Q1 2026, its #1 holding.
  • Royce & Associates first reported a position in Arcosa in Q4 2018 and has held it in 30 quarters since.
  • 372 funds tracked by Wall St. Rank held Arcosa as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.